Vaccinex (NASDAQ:VCNX – Get Free Report) will likely be releasing its resultson Monday, November 16th. Analysts expect Vaccinex to announce earnings of ($73.0380) per share and revenue of $0.33 million for the quarter.
Vaccinex Stock Performance
NASDAQ:VCNX opened at $1.00 on Monday. The company’s 50-day moving average price is $0.95 and its 200-day moving average price is $1.03. The company has a market cap of $2.60 million, a P/E ratio of -0.02 and a beta of 1.10. Vaccinex has a twelve month low of $0.31 and a twelve month high of $1.50.
About Vaccinex
Vaccinex, Inc is a biotechnology company focused on developing antibody-based therapies for cancer and neurodegenerative diseases. The company’s lead product candidate, pepinemab (also known as VX15/2503), is an investigational monoclonal antibody designed to inhibit semaphorin 4D, a signaling protein associated with immune suppression, tumor progression and inflammation.
Vaccinex has evaluated pepinemab in clinical studies involving conditions such as head and neck cancer, metastatic breast cancer, Huntington’s disease and Alzheimer’s disease.
Further Reading
- Five stocks we like better than Vaccinex
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.
